Speakers
Ercem Atillasoy
Chief Regulatory & Safety Officer
AlloVir
Day One
Wednesday April 21
11:40 am | Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives
12:30 pm | Q&A/Discussion
Martin Everett
Chief Scientific Officer
AntaBio
Day One
Wednesday April 21
4:00 pm | Pseudomonas Elastase (LasB) as a Therapeutic Target
4:50 pm | Q&A/Discussion
Glenn Dale
Chief Development Officer
BioVersys
Day Two
Thursday April 22
11:15 am | BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections
12:30 pm | Q&A/Discussion
Kevin Outterson
Executive Director & Professor of Law
CARB-X & Boston University
Day One
Wednesday April 21
9:25 am | Surviving FDA Approval of your Antibiotic
10:15 am | Q&A/Discussion
Cara Cassino
Executive Vice President of R&D & Chief Medical Officer
ContraFect
Day Two
Thursday April 22
9:00 am | Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections
9:50 am | Q&A/Discussion
David Altarac
Chief Medical Officer
Entasis Therapeutics
Day Two
Thursday April 22
12:05 pm | Targeted Therapy for Rare Pathogens: Challenges & Opportunities
12:30 pm | Q&A/Discussion
Dave Ousterout
Chief Scientific Officer
Locus Biosciences
Day One
Wednesday April 21
3:05 pm | Q&A/Discussion
1:50 pm | Clinical Experience with crPhage in Urinary Tract Infections
Silas Holland
Head of External Affairs (Interim) & Director of Global Public Policy
The AMR Action Fund & Merck
Day One
Wednesday April 21
9:00 am | AMR Action Fund: Strengthening & Accelerating Antibiotic Development
10:15 am | Q&A/Discussion
Mike Gordeev
Chief Scientific Officer
MicuRx Pharmaceuticals
Day Two
Thursday April 22
2:10 pm | Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections
3:25 pm | Q&A/Discussion
John George
Co-Founder & Chief Scientific Officer
Oppilotech
Day Two
Thursday April 22
3:25 pm | Q&A/Discussion
3:00 pm | Computational Modelling to Aid Target Discovery
Jonathan Steckbeck
Founder, President & Chief Executive Officer
Peptilogics
Day One
Wednesday April 21
12:05 pm | Differentiated Approach to Harnessing Novel Biologics & Overcome AMR
12:30 pm | Q&A/Discussion
Jeanette Mucha
Chief Executive Officer & Co- Founder
SciBac
Day One
Wednesday April 21
3:05 pm | Q&A/Discussion
2:40 pm | Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections
Angela Talley
Vice President of Clinical Development
Spero Therapeutics
Day Two
Thursday April 22
11:40 am | Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need
12:30 pm | Q&A/Discussion
David Powell
Chief Scientific Officer
Summit Therapeutics
Day Two
Thursday April 22
9:25 am | Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority
9:50 am | Q&A/Discussion
Nrusingh Mohapatra
Chief Scientific Officer
Techulon
Day Two
Thursday April 22
1:45 pm | Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials
3:25 pm | Q&A/Discussion
Joseph DiMasi
Director of Economic Analysis
Tufts CSDD
Day One
Wednesday April 21
9:50 am | Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways
10:15 am | Q&A/Discussion
Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences
Day One
Wednesday April 21
4:25 pm | Live Bacterial Consortia, a Novel Microbiome- Based Approach for Infection Prevention
4:50 pm | Q&A/Discussion
James Crowe
Director
Vanderbilt Vaccine Center
Day One
Wednesday April 21
2:15 pm | Human Monoclonal Antibodies for Emerging Infections
3:05 pm | Q&A/Discussion
Mohammad Seyedsayamdost
Associate Professor of Chemistry & Molecular Biology
Princeton University
Day Two
Thursday April 22
3:25 pm | Q&A/Discussion
2:35 pm | Cryptic Metabolites as a New Source of Pharmaceutical Leads
Peter Beyer
Senior Advisor and Team Lead
World Health Organization - WHO
Day One
Wednesday April 21
8:30 am | Keynote Presentation: A Review of the Antibacterial Development Pipeline
Steve Sandor
VP, Market Access and Trade
PARATEK PHARMACEUTICALS
Day One
Wednesday April 21
8:20 am | Chair’s Opening Remarks
10:15 am | Q&A/Discussion
12:30 pm | Q&A/Discussion
John White
Vice President, Business Strategy and Commercial Operations
PARATEK PHARMACEUTICALS
Day Two
Thursday April 22
8:50 am | Chair’s Opening Remarks
9:50 am | Q&A/Discussion
12:30 pm | Q&A/Discussion
